Atacicept 28063 (RMS) extension study
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Atacicept
Tumor necrosis factor ligand superfamily member 13 inhibitor|Tumor necrosis factor ligand superfamily member 13B inhibitor
What it measured
Main measures
Parameters related to the main study objective:
Who could take part
Relapsing MS
Inclusion: Inclusion Criteria for Participation in Study 28851: Exclusion: Exclusion Criteria for Participation in Study 28851:
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The main objective of the study is to monitor the long-term safety and tolerability of atacicept administered for up to 5 years to subjects with relapsing multiple sclerosis (RMS).
Loading reviews and guidelines…
Related trials
- Addition of Belimumab to B-cell Depletion in Relapsing-re…
Phase 2 · Stopped early
Stopped early
- A Study of Participants With Relapsing-Remitting Multiple…
Phase 2 · Completed
Results posted, no main test reported
- ATAMS ext
Phase 2 · Stopped early
Stopped early
- Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Hu…
Phase 2 · Stopped early
- ATAMS
Phase 2 · Stopped early
Stopped early
- Atacicept frequent MRI study in RMS
Phase 2 · Ongoing
Still running
History
Started
Dec 2008
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error